Singapore markets closed
  • Straits Times Index

    3,101.93
    +9.82 (+0.32%)
     
  • Nikkei

    28,029.57
    +276.20 (+1.00%)
     
  • Hang Seng

    23,766.69
    -22.24 (-0.09%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • BTC-USD

    54,899.86
    -1,541.77 (-2.73%)
     
  • CMC Crypto 200

    1,392.04
    -49.72 (-3.45%)
     
  • S&P 500

    4,514.59
    -62.51 (-1.37%)
     
  • Dow

    34,432.32
    -207.47 (-0.60%)
     
  • Nasdaq

    14,973.08
    -408.24 (-2.65%)
     
  • Gold

    1,781.40
    +18.70 (+1.06%)
     
  • Crude Oil

    67.16
    +0.66 (+0.99%)
     
  • 10-Yr Bond

    1.3780
    -0.0700 (-4.83%)
     
  • FTSE Bursa Malaysia

    1,501.74
    0.00 (0.00%)
     
  • Jakarta Composite Index

    6,538.51
    -45.31 (-0.69%)
     
  • PSE Index

    7,055.19
    +22.65 (+0.32%)
     

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

·5-min read
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting